Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome: a randomized, double-blind, placebo controlled trial.

Plain-language guide to PMID 8567768 (1995): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin) in 30 women.

Key Facts

PMID: 8567768
Journal: Human reproduction (Oxford, England)
Year: 1995
Study type: Randomized Controlled Trial
Authors: Homburg R et al. (3 authors)
DOI: 10.1093/oxfordjournals.humrep.a135743

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin).

The objective of this study was to explore the effect of cotreatment with recombinant human growth hormone (GH), gonadotrophin-releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG) for induction of ovulation in women with clomiphene resistant polycystic ovary syndrome (PCOS).

Who Took Part

The study group was 30 women.

The age groups tagged for this paper are adults, women only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The women were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Chorionic Gonadotropin, Gonadotropins, Pituitary, Growth Hormone, Infertility, Female, Insulin, Insulin-Like Growth Factor I and Menotropins.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin) in 30 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (Human reproduction (Oxford, England)), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the hCG (human chorionic gonadotropin) compound page, all human trials.

Our Notes on the Compounds

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.

HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.